Clinical Trial Update: Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial update reports safety and immunogenicity results of a booster dose of GSK's Boostrix-Polio vaccine; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• Boostrix-Polio (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine, Adsorbed, with Inactivated Poliovirus Vaccine (DTaP-IPV))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Poliomyelitis, Diphtheria | Phase 4 | Status: COMPLETED | Results posted: 2017-07-05